Cargando…
Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
PURPOSE: To describe the adverse events associated with brolucizumab, in particular the sequence of intraocular inflammation (IOI), retinal vasculitis (RV), and/or retinal vascular occlusion (RO). METHODS: This was an unmasked post hoc analysis of the randomized HAWK/HARRIER clinical trials. Patient...
Autores principales: | Khoramnia, Ramin, Figueroa, Marta S., Hattenbach, Lars-Olof, Pavesio, Carlos E., Anderesi, Majid, Schmouder, Robert, Chen, Yu, de Smet, Marc D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061681/ https://www.ncbi.nlm.nih.gov/pubmed/34932153 http://dx.doi.org/10.1007/s00417-021-05518-0 |
Ejemplares similares
-
Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023) -
Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014) -
Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic
por: Borrelli, Enrico, et al.
Publicado: (2020) -
nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey
por: Schmid, Anke, et al.
Publicado: (2022) -
Impact of intravitreal injection therapy on contrast sensitivity in patients with nAMD and DME
por: Dieke, Sebastian, et al.
Publicado: (2023)